Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluation of Varenicline (Champix) in Smoking Cessation for Patients Post-Acute Coronary Syndrome (EVITA) Trial (EVITA)

This study has been completed.
Sponsor:
Collaborators:
St. Michael's Hospital, Toronto
Sunnybrook Health Sciences Centre
Queen Elizabeth II Health Sciences Centre
Information provided by (Responsible Party):
Mark Eisenberg, McGill University
ClinicalTrials.gov Identifier:
NCT00794573
First received: November 19, 2008
Last updated: March 14, 2016
Last verified: March 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2015
  Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):